Cost Analysis of the Use of Glatiramer Acetate Compared to Interferon-Â in Patients with Relapsing-Remitting Multiple Sclerosis and Spasticity in Spain
Value Health
.
2014 Nov;17(7):A394.
doi: 10.1016/j.jval.2014.08.876.
Epub 2014 Oct 26.
Authors
R Sanchez de la Rosa
1
,
Bujalance L Garcia
2
,
J Meca Lallana
3
Affiliations
1
Teva Pharma, Madrid, Spain.
2
Teva Pharmaceuticals, Madrid, Spain.
3
Virgen de la Arrixaca Hospital, Murcia, Spain.
PMID:
27200920
DOI:
10.1016/j.jval.2014.08.876
No abstract available